Cambridge Cognition Holdings plc (LSE:COG) reported a sharp recovery in new business during 2025, with sales orders rising 73% to £12.8 million and its year-end order book increasing 21% to £16.5 million.
Despite this strong commercial momentum, revenue declined by around 10% to approximately £9.4 million, reflecting a weak opening order book and the long lead times typical of clinical contracts. Cost discipline helped limit the adjusted EBITDA loss to £0.5 million, while operating cash flow turned positive. The company also strengthened its financial position, ending the year with net cash of roughly £0.3 million after reducing borrowings.
Strategically, Cambridge Cognition broadened its reach beyond its traditional clinical and academic base into professional healthcare and consumer health markets. This diversification is expected to support a return to revenue growth in 2026 and provide a more robust foundation for future profitability and cash generation.
From an outlook perspective, the company continues to face challenges linked to declining revenues and ongoing losses, along with pressure on operating and free cash flow, although improvements in equity offer some balance sheet support. Technical indicators present a mixed picture, with short-term momentum offset by a longer-term downtrend and signs of overbought conditions. Valuation remains limited due to the absence of profitability and a lack of dividend yield.
More about Cambridge Cognition Holdings
Cambridge Cognition Holdings plc is a neuroscience-focused technology company that develops digital tools for cognitive assessment. Its platforms are used globally across four key areas: clinical trials in the pharmaceutical industry, academic research into central nervous system disorders, healthcare diagnostics led by physicians, and consumer-focused cognitive health and wellness monitoring.
Leave a Reply